Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: Results of a German multicenter study

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2201-2205

  Sehouli, J ^a   Pietzner, K ^a   Harter, P ^b   Munstedt K ^c   Mahner, S ^d   Hasenburg, A ^e   Camara, O ^f   Wimberger, P ^g   Boehmer, D ^a   Buehling, K J ^d   Richter, R ^a   El Khalfaoui, K ^a   Oskay Ozcelik, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Ovarian cancer; Platinum sensitivity; Prognostic factors

Indexed keywords

CARBOPLATIN; PLATINUM DERIVATIVE;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CANCER GRADING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG SENSITIVITY; FEMALE; GERMANY; HIGH RISK PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77958505529     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq229     Document Type: Article

References (16)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51(1): 15-36.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
3. Rodriguez GC, Soper JT, Berchuck A et al. Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol 1992; 10(10): 1553-1560.
4. Cohen ZR, Suki D, Weinberg JS et al. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol 2004; 66(3): 313-325.
5. Geisler JP, Geisler HE. Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol 1995; 57(2): 246-249.
6. Bruzzone M, Campora E, Chiara S et al. Cerebral metastases secondary to ovarian cancer: still an unusual event. Gynecol Oncol 1993; 49(1): 37-40.
7. Anupol N, Ghamande S, Odunsi K et al. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol 2002; 85(3): 487-492.
8. Pectasides D, Aravantinos G, Fountzilas G et al. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res 2005; 25(5): 3553-3558.
9. Budd GT, Webster KD, Reimer RR et al. Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastases. J Surg Oncol 1983; 24(3): 192-195.
10. Hardy JR, Harvey VJ. Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol 1989; 33(3): 296-300.
11. Pietzner K, Oskay-Oezcelik G, El Khalfaoui K et al. Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res 2009; 29(7): 2793-2798.
12. Kumar L, Barge S, Mahapatra AK et al. Central nervous system metastases from primary epithelial ovarian cancer. Cancer Control 2003; 10(3): 244-253.
13. Mayer RJ, Berkowitz RS, Griffiths CT. Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer 1978; 41(2): 776-783.
14. Kim TJ, Song S, Kim CK et al. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer 2007; 17(6): 1252-1257.
15. Melichar B, Urminska H, Kohlova T et al. Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol 2004; 94(2): 267-276.
16. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008; 68(6): 771-789.